Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA – Get Free Report) was the recipient of a large decrease in short interest in the month of June. As of June 15th, there was short interest totaling 4,540 shares, a decrease of 90.0% from the May 31st total of 45,360 shares. Based on an average trading volume of 92,782 shares, the short-interest ratio is presently 0.0 days. Approximately 0.1% of the shares of the company are short sold.
Analysts Set New Price Targets
Separately, Weiss Ratings lowered shares of Sonoma Pharmaceuticals from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Wednesday, April 29th. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the company presently has a consensus rating of “Sell”.
Get Our Latest Stock Report on SNOA
Sonoma Pharmaceuticals Price Performance
Sonoma Pharmaceuticals (NASDAQ:SNOA – Get Free Report) last announced its quarterly earnings data on Tuesday, June 16th. The company reported ($0.33) earnings per share for the quarter, missing the consensus estimate of ($0.24) by ($0.09). Sonoma Pharmaceuticals had a negative return on equity of 43.95% and a negative net margin of 16.26%.The firm had revenue of $5.56 million during the quarter, compared to analysts’ expectations of $5.57 million.
Hedge Funds Weigh In On Sonoma Pharmaceuticals
A hedge fund recently raised its position in Sonoma Pharmaceuticals stock. DRW Securities LLC raised its holdings in Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA – Free Report) by 257.2% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 60,977 shares of the company’s stock after purchasing an additional 43,907 shares during the period. DRW Securities LLC owned 3.59% of Sonoma Pharmaceuticals worth $222,000 at the end of the most recent reporting period. Institutional investors own 1.95% of the company’s stock.
About Sonoma Pharmaceuticals
Sonoma Pharmaceuticals, Inc is a specialty dermatology company focused on developing and commercializing topical prescription and over-the-counter products for inflammatory and infectious skin conditions. Publicly traded on Nasdaq under the symbol SNOA, the company concentrates its efforts on areas such as acne, rosacea, dermatitis and wound care, aiming to provide physicians and patients with innovative treatment options.
At the heart of Sonoma’s technology platform lies its proprietary Triphasic drug delivery system, which enables the timed release of active ingredients through three distinct gel phases.
Read More
- Five stocks we like better than Sonoma Pharmaceuticals
- MDA Space Targets US Defense Market With $620M Acquisition
- Carnival’s Second Quarter: Is the Stock Still Complicated?
- Domino’s Stock Slides to 52-Week Low as Investors Digest CEO Change
- Microsoft Solves AI’s Biggest Bottleneck With Chevron Deal
Receive News & Ratings for Sonoma Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sonoma Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
